Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.44
GLAXF's Cash to Debt is ranked lower than
75% of the 702 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. GLAXF: 0.44 )
Ranked among companies with meaningful Cash to Debt only.
GLAXF' s 10-Year Cash to Debt Range
Min: 0.06  Med: 0.53 Max: N/A
Current: 0.44
Equity to Asset 0.13
GLAXF's Equity to Asset is ranked lower than
96% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. GLAXF: 0.13 )
Ranked among companies with meaningful Equity to Asset only.
GLAXF' s 10-Year Equity to Asset Range
Min: 0.11  Med: 0.25 Max: 0.4
Current: 0.13
0.11
0.4
Interest Coverage 5.23
GLAXF's Interest Coverage is ranked lower than
87% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2456.17 vs. GLAXF: 5.23 )
Ranked among companies with meaningful Interest Coverage only.
GLAXF' s 10-Year Interest Coverage Range
Min: 0.81  Med: 11.99 Max: 28.06
Current: 5.23
0.81
28.06
F-Score: 6
Z-Score: 2.03
M-Score: -2.01
WACC vs ROIC
9.10%
49.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 45.33
GLAXF's Operating margin (%) is ranked higher than
97% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.81 vs. GLAXF: 45.33 )
Ranked among companies with meaningful Operating margin (%) only.
GLAXF' s 10-Year Operating margin (%) Range
Min: 1.68  Med: 29.06 Max: 36.94
Current: 45.33
1.68
36.94
Net-margin (%) 40.03
GLAXF's Net-margin (%) is ranked higher than
96% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.92 vs. GLAXF: 40.03 )
Ranked among companies with meaningful Net-margin (%) only.
GLAXF' s 10-Year Net-margin (%) Range
Min: 5.76  Med: 20.71 Max: 23.94
Current: 40.03
5.76
23.94
ROE (%) 155.34
GLAXF's ROE (%) is ranked higher than
100% of the 685 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.31 vs. GLAXF: 155.34 )
Ranked among companies with meaningful ROE (%) only.
GLAXF' s 10-Year ROE (%) Range
Min: 16.93  Med: 64.07 Max: 159.76
Current: 155.34
16.93
159.76
ROA (%) 19.94
GLAXF's ROA (%) is ranked higher than
92% of the 706 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. GLAXF: 19.94 )
Ranked among companies with meaningful ROA (%) only.
GLAXF' s 10-Year ROA (%) Range
Min: 3.76  Med: 17.95 Max: 25.46
Current: 19.94
3.76
25.46
ROC (Joel Greenblatt) (%) 118.69
GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.13 vs. GLAXF: 118.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GLAXF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 39.89  Med: 85.11 Max: 148.93
Current: 118.69
39.89
148.93
Revenue Growth (3Y)(%) -4.10
GLAXF's Revenue Growth (3Y)(%) is ranked lower than
78% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. GLAXF: -4.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GLAXF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.1  Med: 5.30 Max: 96.5
Current: -4.1
-4.1
96.5
EBITDA Growth (3Y)(%) -18.40
GLAXF's EBITDA Growth (3Y)(%) is ranked lower than
80% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. GLAXF: -18.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GLAXF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -19.2  Med: 7.00 Max: 93
Current: -18.4
-19.2
93
EPS Growth (3Y)(%) -17.80
GLAXF's EPS Growth (3Y)(%) is ranked lower than
75% of the 452 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.20 vs. GLAXF: -17.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GLAXF' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.9  Med: 7.10 Max: 99.2
Current: -17.8
-35.9
99.2
» GLAXF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 7.33
GLAXF's P/E(ttm) is ranked higher than
95% of the 474 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.20 vs. GLAXF: 7.33 )
Ranked among companies with meaningful P/E(ttm) only.
GLAXF' s 10-Year P/E(ttm) Range
Min: 7.08  Med: 15.41 Max: 41.23
Current: 7.33
7.08
41.23
Forward P/E 18.66
GLAXF's Forward P/E is ranked higher than
65% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.27 vs. GLAXF: 18.66 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 7.50
GLAXF's PE(NRI) is ranked higher than
95% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.00 vs. GLAXF: 7.50 )
Ranked among companies with meaningful PE(NRI) only.
GLAXF' s 10-Year PE(NRI) Range
Min: 7.13  Med: 15.43 Max: 42.04
Current: 7.5
7.13
42.04
P/B 9.82
GLAXF's P/B is ranked lower than
88% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.42 vs. GLAXF: 9.82 )
Ranked among companies with meaningful P/B only.
GLAXF' s 10-Year P/B Range
Min: 5.11  Med: 9.13 Max: 19
Current: 9.82
5.11
19
P/S 2.88
GLAXF's P/S is ranked higher than
55% of the 653 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.30 vs. GLAXF: 2.88 )
Ranked among companies with meaningful P/S only.
GLAXF' s 10-Year P/S Range
Min: 1.71  Med: 2.81 Max: 4.64
Current: 2.88
1.71
4.64
PFCF 28.80
GLAXF's PFCF is ranked higher than
68% of the 273 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.64 vs. GLAXF: 28.80 )
Ranked among companies with meaningful PFCF only.
GLAXF' s 10-Year PFCF Range
Min: 7.94  Med: 16.63 Max: 41.83
Current: 28.8
7.94
41.83
POCF 16.24
GLAXF's POCF is ranked higher than
73% of the 385 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.53 vs. GLAXF: 16.24 )
Ranked among companies with meaningful POCF only.
GLAXF' s 10-Year POCF Range
Min: 6.12  Med: 12.33 Max: 22.24
Current: 16.24
6.12
22.24
EV-to-EBIT 6.01
GLAXF's EV-to-EBIT is ranked higher than
94% of the 489 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.18 vs. GLAXF: 6.01 )
Ranked among companies with meaningful EV-to-EBIT only.
GLAXF' s 10-Year EV-to-EBIT Range
Min: 6.6  Med: 11.90 Max: 134.3
Current: 6.01
6.6
134.3
Shiller P/E 12.30
GLAXF's Shiller P/E is ranked higher than
89% of the 309 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.46 vs. GLAXF: 12.30 )
Ranked among companies with meaningful Shiller P/E only.
GLAXF' s 10-Year Shiller P/E Range
Min: 9.48  Med: 15.58 Max: 21.32
Current: 12.3
9.48
21.32
Current Ratio 1.31
GLAXF's Current Ratio is ranked lower than
78% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. GLAXF: 1.31 )
Ranked among companies with meaningful Current Ratio only.
GLAXF' s 10-Year Current Ratio Range
Min: 0.97  Med: 1.29 Max: 1.78
Current: 1.31
0.97
1.78
Quick Ratio 0.97
GLAXF's Quick Ratio is ranked lower than
76% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. GLAXF: 0.97 )
Ranked among companies with meaningful Quick Ratio only.
GLAXF' s 10-Year Quick Ratio Range
Min: 0.68  Med: 1.01 Max: 1.42
Current: 0.97
0.68
1.42
Days Inventory 204.84
GLAXF's Days Inventory is ranked lower than
83% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.56 vs. GLAXF: 204.84 )
Ranked among companies with meaningful Days Inventory only.
GLAXF' s 10-Year Days Inventory Range
Min: 141.08  Med: 181.17 Max: 326.61
Current: 204.84
141.08
326.61
Days Sales Outstanding 84.38
GLAXF's Days Sales Outstanding is ranked lower than
60% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.45 vs. GLAXF: 84.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLAXF' s 10-Year Days Sales Outstanding Range
Min: 54.62  Med: 74.32 Max: 112.93
Current: 84.38
54.62
112.93

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.69
GLAXF's Dividend Yield is ranked higher than
96% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. GLAXF: 5.69 )
Ranked among companies with meaningful Dividend Yield only.
GLAXF' s 10-Year Dividend Yield Range
Min: 1.11  Med: 5.10 Max: 6.27
Current: 5.69
1.11
6.27
Dividend Payout 0.40
GLAXF's Dividend Payout is ranked higher than
99% of the 391 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. GLAXF: 0.40 )
Ranked among companies with meaningful Dividend Payout only.
GLAXF' s 10-Year Dividend Payout Range
Min: 0.14  Med: 0.76 Max: 2.32
Current: 0.4
0.14
2.32
Dividend growth (3y) 2.00
GLAXF's Dividend growth (3y) is ranked lower than
63% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. GLAXF: 2.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
GLAXF' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 78.3
Current: 2
0
78.3
Yield on cost (5-Year) 7.80
GLAXF's Yield on cost (5-Year) is ranked higher than
97% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. GLAXF: 7.80 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GLAXF' s 10-Year Yield on cost (5-Year) Range
Min: 1.52  Med: 6.99 Max: 8.59
Current: 7.8
1.52
8.59
Share Buyback Rate 1.60
GLAXF's Share Buyback Rate is ranked higher than
94% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.00 vs. GLAXF: 1.60 )
Ranked among companies with meaningful Share Buyback Rate only.
GLAXF' s 10-Year Share Buyback Rate Range
Min: 51.8  Med: 1.20 Max: -20
Current: 1.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.47
GLAXF's Price/Projected FCF is ranked lower than
297% of the 297 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.37 vs. GLAXF: 1.47 )
Ranked among companies with meaningful Price/Projected FCF only.
GLAXF' s 10-Year Price/Projected FCF Range
Min: 0.82  Med: 1.53 Max: 7.53
Current: 1.47
0.82
7.53
Price/Median PS Value 1.02
GLAXF's Price/Median PS Value is ranked lower than
157% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. GLAXF: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
GLAXF' s 10-Year Price/Median PS Value Range
Min: 0.65  Med: 1.10 Max: 2.43
Current: 1.02
0.65
2.43
Price/Peter Lynch Fair Value 0.90
GLAXF's Price/Peter Lynch Fair Value is ranked lower than
608% of the 145 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. GLAXF: 0.90 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
GLAXF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56  Med: 1.35 Max: 3.57
Current: 0.9
0.56
3.57
Earnings Yield (Greenblatt) (%) 16.61
GLAXF's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. GLAXF: 16.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLAXF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.7  Med: 8.40 Max: 16.61
Current: 16.61
0.7
16.61
Forward Rate of Return (Yacktman) (%) 13.44
GLAXF's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 305 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. GLAXF: 13.44 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GLAXF' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 3.9  Med: 13.80 Max: 50.2
Current: 13.44
3.9
50.2

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 37,781 39,222 40,571
EPS($) 1.12 1.20 1.50
EPS without NRI($) 1.12 1.20 1.50

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GSK.USA, GS7.Germany, GSK.Argentina, GSK N.Mexico, GSK.Switzerland, GS7A.Germany,
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatric and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. Its products main categories are: Oral care, Nutritional, Total wellness, and Skin health. Its barands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.
» More Articles for OTCPK:GLAXF

Headlines

Articles On GuruFocus.com
It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
Tweedy Browne Global Value Adds to Eight Stakes in Portfolio Jul 14 2015 
JW1 Jun 29 2015 
JW1 Jun 28 2015 
JW1 Jun 28 2015 
JW1 Jun 28 2015 
Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK Jun 15 2015 
Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK Jun 14 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Hotchkis & Wiley Large Cap Value Fund Q1 2015 Commentary May 22 2015 

More From Other Websites
Why GlaxoSmithKline plc Is A Better Dividend Stock Than BP plc Aug 04 2015
GSK rehires suspected China whistleblower Aug 03 2015
GSK re-hires China government relations executive linked to whistleblower probe Aug 03 2015
GSK re-hires China government relations exec linked to whistleblower probe Aug 03 2015
There's more to Merck's Ebola vaccine than money Jul 31 2015
After Merck success, work goes on with other Ebola vaccines Jul 31 2015
After Merck success, work goes on with other Ebola vaccines Jul 31 2015
Is GlaxoSmithKline plc More Likely To Double In Value Than Hikma Pharmaceuticals Plc? Jul 31 2015
GlaxoSmithKline (GSK) Earnings Report: Q2 2015 Conference Call Transcript Jul 30 2015
Should You Splash The Cash On GlaxoSmithKline plc, Bodycote PLC And RPS Group plc? Jul 30 2015
Glaxo Up on Q2 Earnings Beat, Revenues Rise, View Same - Analyst Blog Jul 30 2015
Romania investigates suspected drug company bribes Jul 30 2015
Advair revenue down again, but GSK looks to next-gen (and Zebulon) for replacement revenue Jul 29 2015
GlaxoSmithKline sees staged roll-out of malaria vaccine Jul 29 2015
Exclusive - GSK faces new corruption allegations, this time in Romania Jul 29 2015
Exclusive - GSK faces new corruption allegations, this time in Romania Jul 29 2015
Exclusive - GSK faces new corruption allegations, this time in Romania Jul 29 2015
Exclusive: GSK faces new corruption allegations, this time in Romania Jul 29 2015
GSK Boosted by New Vaccines Jul 29 2015
GSK jumps 3% on strong EPS; Advair sales slump Jul 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK